Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Dr. Amy Reed, Anti-Power Morcellator Activist, Dead At 44

Executive Summary

Anesthesiologist Amy Reed, who with her cardiologist husband Hooman Noorchasm turned her battle against uterine cancer into a crusade to abolish unsafe uses of power morcellators, died May 24 at her home in Yardley, Pa., at the age of 44.

You may also be interested in...



Citizen Petition Raises Concerns About Robotic Mastectomy Trial

One doctor is using his expertise to advocate for better premarket surveillance of cancer-treatment devices.

Pennsylvania Lawmaker Wants Power Morcellators Reviewed In Cancer 'Moonshot' Initiative

Pennsylvania Republican Congressman Mike Fitzpatrick sent a letter to Vice President Joe Biden asking for reforms to medical device review processes, and for a sharper look at power morcellators that he said spreads cancer as part of the administration's cancer "moonshot" initiative.

FDA Puts Black Box Warning On Power Morcellators With Immediately-In-Effect Guidance

FDA has followed through on the advice of its advisory panel by requiring new labeling for power morcellators used to treat uterine fibroids, emphasizing the procedure’s potential to spread cancer. FDA wants to restrict the power morcellation procedure to younger women who are interested in maintaining their ability to have children and who have been thoroughly informed of the risks.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT104928

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel